IL4 and neoplasm: This chimeric cytokine receptor also showed efficacy in a pancreatic cancer model: T cells modified to express a chimeric antigen receptor targeting prostate stem cell antigen (PSCA), found in pancreatic tumors, maintained their antitumor activity in an IL4-rich tumor microenvironment when they are co-transduced with the IL4/IL7 CcR (39).